Therefore, at present, EGFR positivity represents a therapeutic advantage to delay tumor progression by using specific tyrosine-kinase inhibitors, which improves survival and reduces the relapse of lung cancer, thus leading to a better prognosis [23,24], even considering that EGFR positivity is often associated with PD-L1 negativity [25]. The gene discussed is EGFR; the disease is lung carcinoma.